Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

NewAmsterdam Pharma's obicetrapib lowers LDL-C in Phase 3 trials, showing promise as a CETP inhibitor. Read more on NAMS ...

Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...

ARS Pharmaceuticals (SPRY) announced that the FDA has approved neffy 1 mg for the treatment of Type I Allergic Reactions, including ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the approval and ...

Kennedy can provide doctors and healthcare professionals with the information they need to truly determine if a drug is safe, ...

ITM Isotope Technologies Munich SE is gearing up to enter the US market with its radiopharmaceutical therapy, ITM-11 ...

AstraZeneca Pharma India has received approval from CDSCO to import and distribute the cancer treatment drug Durvalumab ...

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...